Dr. Stanley Nattel stands as a preeminent figure in the field of cardiovascular medicine and electrophysiology, recognized globally for his transformative contributions to understanding cardiac rhythm disorders. He currently holds the prestigious Paul David Chair in Cardiovascular Electrophysiology at the University of Montreal while serving as Director of the Electrophysiology Research Program at the Montreal Heart Institute. Dr. Nattel established his research career at the University of Montreal and the Montreal Heart Institute in 1987, quickly rising to prominence for his innovative approaches to cardiac electrophysiology. From 1990 to 2004, he provided visionary leadership as Scientific Director of the Montreal Heart Institute Research Center, significantly expanding its research capacity and international reputation.
Professor Nattel's groundbreaking research has fundamentally advanced the understanding of cardiac arrhythmias through his pioneering investigations into the fundamental mechanisms of cardiac bioelectricity and electrical conduction in the heart. His seminal work on the mechanisms of action of antiarrhythmic drugs, basic electrical properties of the human heart, and the pathophysiology of atrial fibrillation has established new paradigms in cardiovascular therapeutics. With an impressive scholarly output including 398 peer-reviewed articles, 27 non peer-reviewed publications, and 29 book chapters, his research has directly contributed to improved clinical management of cardiovascular disease and the development of innovative treatment approaches. His translational research has led to multiple patent applications, including novel approaches using statin drugs to treat atrial fibrillation and targeting acetylcholine-dependent current as a new ionic target for atrial fibrillation therapy.
Beyond his research contributions, Dr. Nattel has profoundly influenced the field through extensive mentorship and academic leadership, having supervised 120 students throughout his distinguished career. He has served on 19 editorial boards and contributed to the scientific community through 251 invited lectures at major international conferences, establishing himself as a sought-after authority in cardiac electrophysiology. His expertise is further recognized through his membership on scientific advisory boards for six companies and consultations with more than 30 pharmaceutical and medical device organizations. Currently, Dr. Nattel continues to push the boundaries of cardiac electrophysiology research, focusing on innovative therapeutic approaches for cardiac arrhythmias while training the next generation of cardiovascular researchers who will carry forward his legacy of scientific excellence.
